Jane Street Group LLC Has $344,000 Holdings in MEDNAX Inc (MD)
Jane Street Group LLC decreased its position in shares of MEDNAX Inc (NYSE:MD) by 79.5% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 7,979 shares of the company’s stock after selling 30,893 shares during the quarter. Jane Street Group LLC’s holdings in MEDNAX were worth $344,000 as of its most recent SEC filing.
A number of other institutional investors have also recently added to or reduced their stakes in MD. Cornerstone Capital Management Holdings LLC. purchased a new stake in MEDNAX in the third quarter worth approximately $5,229,000. Asset Management One Co. Ltd. boosted its position in shares of MEDNAX by 1.5% during the third quarter. Asset Management One Co. Ltd. now owns 152,185 shares of the company’s stock worth $6,562,000 after buying an additional 2,176 shares during the period. AMP Capital Investors Ltd boosted its position in shares of MEDNAX by 61.3% during the third quarter. AMP Capital Investors Ltd now owns 121,984 shares of the company’s stock worth $5,258,000 after buying an additional 46,340 shares during the period. Caisse DE Depot ET Placement DU Quebec boosted its holdings in MEDNAX by 1,316.7% in the third quarter. Caisse DE Depot ET Placement DU Quebec now owns 256,420 shares of the company’s stock valued at $11,103,000 after purchasing an additional 238,320 shares during the period. Finally, Engineers Gate Manager LP purchased a new position in MEDNAX in the third quarter valued at $474,000. Hedge funds and other institutional investors own 98.43% of the company’s stock.
A number of brokerages have issued reports on MD. Piper Jaffray Companies began coverage on MEDNAX in a report on Wednesday, December 13th. They set an “overweight” rating and a $58.00 price target for the company. Citigroup decreased their price target on MEDNAX from $52.00 to $47.00 and set a “neutral” rating for the company in a report on Friday, November 3rd. Robert W. Baird lifted their price target on MEDNAX from $47.00 to $48.00 and gave the stock a “neutral” rating in a report on Friday, November 3rd. Jefferies Group reaffirmed a “hold” rating and set a $44.00 price target on shares of MEDNAX in a report on Friday, November 3rd. Finally, KeyCorp set a $51.00 target price on MEDNAX and gave the stock a “buy” rating in a research report on Wednesday, November 1st. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the company’s stock. MEDNAX presently has a consensus rating of “Hold” and an average target price of $53.70.
Shares of MEDNAX Inc (NYSE:MD) opened at $52.02 on Wednesday. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 0.62. MEDNAX Inc has a 52-week low of $40.56 and a 52-week high of $72.13. The company has a market capitalization of $4,814.82, a PE ratio of 15.72, a PEG ratio of 1.66 and a beta of 0.40.
MEDNAX (NYSE:MD) last posted its earnings results on Wednesday, November 1st. The company reported $0.87 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.87. MEDNAX had a return on equity of 10.80% and a net margin of 7.76%. The business had revenue of $868.95 million for the quarter, compared to analysts’ expectations of $864.78 million. During the same quarter in the previous year, the firm earned $1.09 earnings per share. The business’s revenue was up 4.9% compared to the same quarter last year. research analysts forecast that MEDNAX Inc will post 3.1 EPS for the current fiscal year.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Stock Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related stocks with our FREE daily email newsletter.